Maria Tsikala-Vafea1, Neel Belani2, Kendra Vieira1, Hina Khan3, Dimitrios Farmakiotis4. 1. Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, RI, USA. 2. Division of Hematology-Oncology, The Warren Alpert Medical School of Brown University, Providence, RI, USA. 3. Department of Internal Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, USA. 4. Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: dimitrios.farmakiotis@lifespan.org.
Abstract
OBJECTIVES: Observational and experimental studies suggest that the use of antibiotics close to administration of immune checkpoint inhibitors (ICI) can have a negative effect on tumour response and patient survival, due to microbiome dysbiosis and the resultant suppression of host immune response against neoplastic cells. METHODS: A systematic search of PUBMED and EMBASE was undertaken for studies published between 1 January 2017 and 1 June 2020, evaluating the association between the use of antibiotics and clinical outcomes in patients with cancer treated with ICIs. A meta-analysis of the association between the use of antibiotics and clinical outcomes was also performed. RESULTS: Forty-eight studies met the inclusion criteria (12,794 patients). Use of antibiotics was associated with shorter overall survival [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.59-2.22; adjusted HR 1.87, 95% CI 1.55-2.25] and progression-free survival (HR 1.52, 95% CI 1.36-1.70; adjusted HR 1.93, 95% CI 1.59-2.36), decreased response rate [odds ratio (OR) 0.54, 95% CI 0.34-0.86] and more disease progression (OR 2.00, 95% CI 1.27-3.14). The negative association between the use of antibiotics and progression-free survival was stronger in patients with renal cell carcinoma or melanoma compared with lung cancer. Only antibiotic administration >1 month prior to ICI initiation was associated with increased disease progression. Heterogeneity was substantial for all outcomes. CONCLUSIONS: Recent use of antibiotics in patients with cancer treated with ICIs was associated with worse clinical outcomes. Such patients may benefit from dedicated antimicrobial stewardship programmes.
OBJECTIVES: Observational and experimental studies suggest that the use of antibiotics close to administration of immune checkpoint inhibitors (ICI) can have a negative effect on tumour response and patient survival, due to microbiome dysbiosis and the resultant suppression of host immune response against neoplastic cells. METHODS: A systematic search of PUBMED and EMBASE was undertaken for studies published between 1 January 2017 and 1 June 2020, evaluating the association between the use of antibiotics and clinical outcomes in patients with cancer treated with ICIs. A meta-analysis of the association between the use of antibiotics and clinical outcomes was also performed. RESULTS: Forty-eight studies met the inclusion criteria (12,794 patients). Use of antibiotics was associated with shorter overall survival [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.59-2.22; adjusted HR 1.87, 95% CI 1.55-2.25] and progression-free survival (HR 1.52, 95% CI 1.36-1.70; adjusted HR 1.93, 95% CI 1.59-2.36), decreased response rate [odds ratio (OR) 0.54, 95% CI 0.34-0.86] and more disease progression (OR 2.00, 95% CI 1.27-3.14). The negative association between the use of antibiotics and progression-free survival was stronger in patients with renal cell carcinoma or melanoma compared with lung cancer. Only antibiotic administration >1 month prior to ICI initiation was associated with increased disease progression. Heterogeneity was substantial for all outcomes. CONCLUSIONS: Recent use of antibiotics in patients with cancer treated with ICIs was associated with worse clinical outcomes. Such patients may benefit from dedicated antimicrobial stewardship programmes.
Authors: Patricia Iranzo; Ana Callejo; Juan David Assaf; Gaspar Molina; Daniel Esteban Lopez; David Garcia-Illescas; Nuria Pardo; Alejandro Navarro; Alex Martinez-Marti; Susana Cedres; Caterina Carbonell; Joan Frigola; Ramon Amat; Enriqueta Felip Journal: Front Med (Lausanne) Date: 2022-05-30
Authors: Andrew F Nyein; Shahla Bari; Stephanie Hogue; Yayi Zhao; Bradley Maller; Sybil Sha; Maria F Gomez; Dana E Rollison; Lary A Robinson Journal: BMC Cancer Date: 2022-01-24 Impact factor: 4.430
Authors: Annika Yanina Classen; Michael Sandherr; Jörg Janne Vehreschild; Marie von Lilienfeld-Toal Journal: Onkologe (Berl) Date: 2022-03-15 Impact factor: 0.170
Authors: Ashray Gunjur; Andrea J Manrique-Rincón; Oliver Klein; Andreas Behren; Trevor D Lawley; Sarah J Welsh; David J Adams Journal: J Pathol Date: 2022-05-20 Impact factor: 9.883